Breakthrough Study Shows AEYE-DS AI Achieves 96% Screening Success in Endocrinology Clinics

AEYE-DS Autonomous AI Screening Reaches New Heights

AEYE Health, a leader in ophthalmic artificial intelligence and retinal diagnostics, has made headlines with its latest study published in the British Journal of Ophthalmology. This research spotlights the AEYE Diagnostic Screening (AEYE-DS) system, which showcases an astounding 96% success rate in identifying diabetic retinopathy in a bustling endocrinology clinic without the need for eye dilation.

Study Overview

In collaboration with researchers from the Sheba Medical Center in Israel and the Icahn School of Medicine at Mount Sinai in New York, the study evaluated 256 adults with diabetes at their point of care. It demonstrated how effectively AEYE-DS integrates into the daily workflows of healthcare providers, facilitating diabetic eye screenings directly during routine check-ups. This innovative approach is crucial, as it saves time for specialists and minimizes the various barriers that often deter patients from getting necessary eye exams.

The Challenge of Diabetic Eye Screening

Diabetic retinopathy represents the leading cause of preventable blindness in working-age adults, particularly in the United States. Despite the recommendation for annual dilated eye exams, over 60% of diabetic patients forego these critical check-ups due to a lack of accessible specialists, geographic challenges, and the logistical hurdles of scheduling appointments.

The AEYE-DS addresses this issue by shifting screenings to the patient's immediate treatment point. This allows doctors to concentrate on delivering treatment while ensuring that patients receive necessary screenings. In the context of a busy clinic, the key performance metric for this approach is imageability—the technology’s capability to reliably produce definitive results with minimal operator intervention.

Impressive Results

During the study, the AEYE-DS system, paired with the Topcon NW500 non-mydriatic camera, delivered results for approximately 95.7% of all patients seen, requiring just an hour of training for the operator. This level of success in a real-world setting substantiates previous clinical trials that reported nearly perfect outcomes with no need for dilating medication.

Dr. Gal Yaakov Cohen, the study's lead author from Mount Sinai, emphasizes the significance of these findings, stating that the AEYE-DS effectively tackled the low imageability issue that has persistently hampered diabetic retinopathy screening programs. The ability to provide consistent results without requiring dilating eye drops is game-changing for patient screenings.

Enhancing Patient Care

The study also revealed high patient satisfaction rates, with an impressive average rating of 4.5 out of 5. Almost 90% of patients reported the system as easy to use, and 90% indicated they would recommend the screening to other diabetes patients. This feedback validates AEYE-DS’s role in facilitating patient-friendly screening procedures, bringing essential eye care to those who might otherwise overlook it.

The research demonstrated that by utilizing AEYE-DS during routine endocrinology visits, healthcare providers could swiftly identify patients approaching immediate treatment needs due to confirmed cases of diabetic retinopathy. This direct detection approach not only streamlines the process but also ensures timely referral for critical care, safeguarding patient vision at the onset of potential complications.

Closing the Clinical Loop

A noteworthy feature of the AEYE-DS study lies in its integration into established clinical workflows. By avoiding routine dilation for most scans, the process allows patients requiring further examination to be referred directly to specialized ophthalmology departments without unnecessary delays. For the scans that were gradable, AEYE-DS produced interpretive notes ready for specialists to integrate into their patient records, enhancing the overall efficiency and productivity of clinical operations.

Zack Dvey-Aharon, Co-founder and CEO of AEYE Health, underlines the transformative potential of these findings, positing that the AEYE-DS automated AI is positioned to revolutionize diabetic eye screening protocols across the country, ultimately aiming to prevent blindness caused by diabetes.

AEYE Health stands out in digital health, focusing on delivering advanced, fully autonomous AI screening solutions tailored for retinal imaging. Their flagship product, AEYE-DS, is recognized as the quickest growing system for diabetic eye examinations in the U.S., striving to enhance accessibility and accuracy in health diagnostics. This pivotal study reaffirms AEYE Health's commitment to advancing eye care in diabetes management, ensuring a future where vision health is prioritized for every patient.